Welcome to our dedicated page for KAZIA THERAPEUTICS SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KAZIA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KAZIA THERAPEUTICS's regulatory disclosures and financial reporting.
Kazia Therapeutics reported that VP, Finance and Controller Jeffrey Bonacorda received a grant of employee stock options over 150,000 ADSs. These options have an exercise price of $6.78 per ADS, set by reference to the Nasdaq closing price on January 8, 2026.
One-third of the options vest on January 8, 2027, with the remaining two-thirds vesting in equal annual tranches on each anniversary of that date. The options were granted for no cash consideration, are held directly, and will expire on January 8, 2029, if not exercised.
Kazia Therapeutics Ltd director Ebru Davidson received a board-approved grant of 100,000 employee stock options over ADSs. The options carry an exercise price of $9.10 per ADS, were granted for no cash consideration, vest on January 8, 2027, and expire on January 8, 2029. Following this award, Davidson holds 100,000 derivative securities directly.
KAZIA THERAPEUTICS LTD reported a compensation-related equity grant to executive David Cain, Director, CMC. He received 100,000 employee stock options over ADSs, with an exercise price of $9.10 per ADS and no cash consideration for the grant. One-third of the options vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches on each anniversary of that date. The options expire on January 8, 2029, creating a multi-year incentive tied to the company’s share performance.
Kazia Therapeutics Ltd director Robert F. Apple received a grant of stock options over 75,000 ADSs on January 8, 2026. The options have an exercise price of $6.78 per ADS, were granted for no cash consideration, and vest on January 8, 2027. They expire on January 8, 2029, and represent his full reported option holdings from this award.
Kazia Therapeutics reported that Chief Financial Officer James E. Levine received an award of 200,000 employee stock options over ADSs, with an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026, and the remaining two-thirds vest in equal yearly tranches on each anniversary of that date.
The options were granted for no consideration and expire on June 19, 2029. All options held by Levine will be forfeited if he voluntarily leaves the company before the first anniversary of the commencement date. Following this grant, he holds 200,000 derivative securities directly.
Kazia Therapeutics Ltd reported that Chief Scientific Officer Sudha Rao received a grant of 250,000 employee stock options over ADSs. The options have an exercise price of $18.48 per ADS, were granted for no cash consideration, and are held directly.
One-third of the options vest on April 13, 2026, with the remaining two-thirds vesting in equal yearly tranches on each anniversary of that date, subject to continued service. All options will be forfeited if she voluntarily leaves before the first anniversary. Any unexercised options expire on June 19, 2029. After this grant, she holds 250,000 options in total.
Kazia Therapeutics Ltd director-level insider James E. Levine, the company’s Chief Financial Officer, has filed a Form 3 initial statement of beneficial ownership. The provided data show no reported purchases, sales, exercises, gifts, or other transactions, reflecting only his status as a reporting officer.
Kazia Therapeutics director Ebru Davidson has filed an initial ownership report outlining existing option-based exposure to the company’s American Depositary Shares (ADSs). The filing shows two ADS option positions, each giving the right to buy ADSs at fixed exercise prices before their respective expiration dates.
One ADS option covers 75,000 underlying ADSs at an exercise price of $8.0000 per ADS, expiring on July 3, 2027. Another ADS option covers 2,000 underlying ADSs at an exercise price of $0.3348 per ADS, expiring on April 30, 2027. Footnotes explain that one grant vests in equal quarterly installments over three years beginning April 30, 2024, while another vested 100% on July 3, 2025, in each case conditioned on continued service.
Kazia Therapeutics files a prospectus supplement registering 10,700,211 American Depositary Shares, representing 5,350,105,500 ordinary shares. The supplement incorporates a Form 6-K furnished June 2, 2026, which discloses the appointment of James Levine as Chief Financial Officer, effective June 1, 2026.
Mr. Levine’s employment terms include an annual base salary of $475,000, an annual target bonus equal to 40% of base salary (prorated for 2026), and a proposed grant, subject to Board approval, of options over 200,000 ADSs with one-third vesting on commencement and the balance vesting in equal yearly installments. Severance and post-termination benefits are described in the Employment Agreement filed as Exhibit 10.1.
Kazia Therapeutics Limited files a prospectus supplement registering 232,956 American Depositary Shares. The supplement, dated June 2, 2026, incorporates a Form 6-K that announces the appointment of James Levine as Chief Financial Officer effective June 1, 2026, and summarizes his employment terms.
The prospectus supplement states the ADSs trade on Nasdaq under the symbol KZIA and notes a reported last sale price of $12.56 per ADS as of June 1, 2026. The Form 6-K discloses Mr. Levine’s US$475,000 base salary, a 40% target bonus (prorated for 2026), and a 200,000 ADS option grant subject to Board approval and vesting terms. Employment and severance provisions are summarized in the furnished Employment Agreement (Exhibit 10.1).